De­spite wor­ries trig­gered by im­bal­ance of deaths, Sh­ionogi's an­tibi­ot­ic clears FDA pan­el vote

Con­cerns over dis­pro­por­tion­ate mor­tal­i­ty had not stopped a pan­el of ex­perts to rec­om­mend that the FDA ap­prove Sh­iono­gi’s an­tibi­ot­ic ce­fide­ro­col for com­pli­cat­ed uri­nary tract in­fec­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.